ClinicalTrials.gg
TerminatedNCT03841773RECOVERYUpdated Feb 6, 2025Results posted

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD

A Phase 3 interventional study of TNX-102 SL and Placebo SL Tablets in PTSD, sponsored by Tonix Pharmaceuticals, Inc.. Terminated at 30 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-06.

Sponsored by Tonix Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Why this study was terminated
Interim Analysis results

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States — 341 open to participants now, 404 under way, 18 of them phase 3. Stress Disorders, Post-Traumatic · United States.

Enrollment
259th of 1,491
192 · median 65
Started
2019
with 93 others
Phase 3
64 of 1,664
8 open now
Registered
906th of 1,664
by date

Among the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, this one is the 259th largest by enrollment of the 1,491 interventional ones that give a count, is one of 94 that started in 2019, is one of 64 in phase 3, and was the 906th registered.

Stress Disorders, Post-Traumatic

2,687 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

341 of the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States are open now. Recruiting first, the newest first:

336 more — sign in →

All 341 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, or all of them as a file.
02

Study summary

This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose study that will investigate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) - a sublingual formulation of cyclobenzaprine. Following successful screening and randomization, eligible patients will have a telephonic visit at week 2 and then return regularly to the study clinic for monthly visits for assessments of efficacy and safety.

03

Conditions studied

  • PTSD

Keywords

  • PTSD
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and Female subjects between the years of 18-75 with a diagnosis of PTSD (diagnosis can be made at screening)
  • Index trauma must have occurred within 9 years of Screening Visit
  • Must have occurred when the patient was ≥18 years of age

Exclusion criteria

Exclusion Criteria:

  • Use of antidepressant medication within 2 months of Baseline
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
192 participants (actual)

Study arms

  • Experimental
    TNX-102 SL Tablet 2.8 mg

    2 x TNX-102 SL, 2.8 mg Tablets taken sublingually each day at bedtime for 12 weeks.

    Drug: TNX-102 SL

  • Placebo comparator
    Placebo SL Tablet

    2 x Placebo Tablets taken sublingually each day at bedtime for 12 weeks.

    Drug: Placebo SL Tablets

Interventions

  • Patients will take 2 tablets of randomly assigned study drug sublingually starting on Day 1 for 12 weeks

    Also known as: Low dose cyclobenzaprine sublingual tablets, Tonmya(R)

  • DrugPlacebo SL Tablets

    Patients will take 2 tablets of randomly assigned study drug sublingually starting on Day 1 for 12 weeks

    Also known as: Placebo sublingual tablets, TNX-102 SL Placebo Tablets

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in the Total CAPS-5 Score

    The primary efficacy endpoint is the mean change from baseline (Day 1) in the total CAPS-5 score after 12 weeks of treatment. The CAPS-5 is an updated and validated version of a semi-structured interview that has been designed to assess the essential features of PTSD as defined by the DSM-5. The total score ranges from 0 to 80 with higher scores indicating more severe PTSD symptoms.

    Time frame: Day 1, Week 12

Secondary outcomes

  1. Clinical Global Impression of Severity (CGI-S)

    Change from baseline (Day 1) in CGI-S score at Week 12. CGI-S range from 1 (Normal, not ill at all) to 7 (Among the most extremely ill patients).

    Time frame: Day 1, Week 12

  2. Sheehan Disability Scale (SDS)

    Change from baseline in Sheehan Disability Scale (SDS) total score after 12 weeks of treatment comparing the 5.6 mg treatment arm to placebo. The SDS is a self-report questionnaire that was designed to assess the participant's view of the degree to which symptoms have disrupted work/school, social life/leisure activities, and family life/home responsibilities during the previous two weeks. Score ranges from 0 to 30. A score of 0 means the patient is unimpaired, and a score of 30 means the patient is highly impaired.

    Time frame: Day 1, Week 12

  3. Patient-Reported Outcome Measurement Information System (PROMIS) Sleep Disturbance

    Change from baseline (Day 1) to Week 12 in the PROMIS Sleep Disturbance scale. The PROMIS Sleep disturbance short form 8a consists of 8 questions on a 5-point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40. Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10.

    Time frame: Day 1, Week 12

07

Results

Posted Feb 6, 2025

Participant flow

Participant flow — Overall Study
MilestonePlacebo SL TabletTNX-102 SL Tablet, 5.6 mg
Started9399
Completed6459
Not completed2940

Outcome measures

PrimaryMean Change From Baseline in the Total CAPS-5 Score

The primary efficacy endpoint is the mean change from baseline (Day 1) in the total CAPS-5 score after 12 weeks of treatment. The CAPS-5 is an updated and validated version of a semi-structured interview that has been designed to assess the essential features of PTSD as defined by the DSM-5. The total score ranges from 0 to 80 with higher scores indicating more severe PTSD symptoms.

Time frame:
Day 1, Week 12
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline in the Total CAPS-5 Score
units on a scalePlacebo SL TabletTNX-102 SL Tablet, 5.6 mg
Mean Change From Baseline in the Total CAPS-5 Score-18.5 ± 1.90-20.7 ± 1.97
SecondaryClinical Global Impression of Severity (CGI-S)

Change from baseline (Day 1) in CGI-S score at Week 12. CGI-S range from 1 (Normal, not ill at all) to 7 (Among the most extremely ill patients).

Time frame:
Day 1, Week 12
Reported as:
Least squares mean · units on a scale
Clinical Global Impression of Severity (CGI-S)
units on a scalePlacebo SL TabletTNX-102 SL Tablet, 5.6 mg
Clinical Global Impression of Severity (CGI-S)-1.5 ± 0.17-2.0 ± 0.18
SecondarySheehan Disability Scale (SDS)

Change from baseline in Sheehan Disability Scale (SDS) total score after 12 weeks of treatment comparing the 5.6 mg treatment arm to placebo. The SDS is a self-report questionnaire that was designed to assess the participant's view of the degree to which symptoms have disrupted work/school, social life/leisure activities, and family life/home responsibilities during the previous two weeks. Score ranges from 0 to 30. A score of 0 means the patient is unimpaired, and a score of 30 means the patient is highly impaired.

Time frame:
Day 1, Week 12
Reported as:
Least squares mean · units on a scale
Sheehan Disability Scale (SDS)
units on a scalePlacebo SL TabletTNX-102 SL Tablet, 5.6 mg
Sheehan Disability Scale (SDS)-7.6 ± 0.97-9.4 ± 1.01
SecondaryPatient-Reported Outcome Measurement Information System (PROMIS) Sleep Disturbance

Change from baseline (Day 1) to Week 12 in the PROMIS Sleep Disturbance scale. The PROMIS Sleep disturbance short form 8a consists of 8 questions on a 5-point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40. Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10.

Time frame:
Day 1, Week 12
Reported as:
Least squares mean · T-score
Patient-Reported Outcome Measurement Information System (PROMIS) Sleep Disturbance
T-scorePlacebo SL TabletTNX-102 SL Tablet, 5.6 mg
Patient-Reported Outcome Measurement Information System (PROMIS) Sleep Disturbance-9.4 ± 1.51-13.0 ± 1.57

Adverse events

Collected over 14 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo SL Tablet0/93 (0%)2/91 (2.2%)17/91 (18.7%)
TNX-102 SL Tablet, 5.6 mg0/99 (0%)0/96 (0%)46/96 (47.9%)
Most frequent serious events
Most frequent serious events
EventPlacebo SL TabletTNX-102 SL Tablet, 5.6 mg
Cholecystic AcuteHepatobiliary disorders1/910/96
Anaphylactic reactionImmune system disorders1/910/96
AbcessInfections and infestations1/910/96
Jaw FractureInjury, poisoning and procedural complications1/910/96
Most frequent other events
Most frequent other events
EventPlacebo SL TabletTNX-102 SL Tablet, 5.6 mg
Hypoaesthesia OralGastrointestinal disorders1/9128/96
Dry MouthGastrointestinal disorders3/918/96
Paraesthesia OralGastrointestinal disorders1/917/96
NauseaGastrointestinal disorders5/911/96
HeadacheNervous system disorders5/913/96
Tongue DiscomfortGastrointestinal disorders0/915/96
Upper respiratory tract infectionInfections and infestations4/915/96

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo SL TabletTNX-102 SL Tablet, 5.6 mgTotal
Mean37.2 ± 10.6739.8 ± 11.6138.5 ± 11.16
Sex: Female, Male
Sex: Female, Male(Participants)Placebo SL TabletTNX-102 SL Tablet, 5.6 mgTotal
Female7478152
Male192140
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo SL TabletTNX-102 SL Tablet, 5.6 mgTotal
Hispanic or Latino161935
Not Hispanic or Latino7780157
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo SL TabletTNX-102 SL Tablet, 5.6 mgTotal
American Indian or Alaska Native112
Asian033
Native Hawaiian or Other Pacific Islander516
Black or African American111526
White7173144
More than one race224
Unknown or Not Reported347
Region of Enrollment
Region of Enrollment(participants)Placebo SL TabletTNX-102 SL Tablet, 5.6 mgTotal
United States9399192
08

Study locations

30 sites
  • Ashild Peters
    Phoenix, Arizona 85012, United States
  • Ashild Peters
    Little Rock, Arkansas 72211, United States
  • Ashild Peters
    Rogers, Arkansas 72758, United States
  • Ashild Peters
    Beverly Hills, California 90210, United States
  • Ashild Peters
    Oceanside, California 92056, United States
  • Ashild Peters
    Orange, California 92868, United States
  • Ashild Peters
    Panorama City, California 91402, United States
  • Ashild Peters
    Riverside, California 92506, United States
  • Ashild Peters
    San Diego, California 92123, United States
  • Ashild Peters
    Temecula, California 92591, United States
  • Ashild Peters
    Colorado Springs, Colorado 80910, United States
  • Ashild Peters
    Norwich, Connecticut 06360, United States
  • Ashild Peters
    Washington, District of Columbia 20011, United States
  • Ashild Peters
    Jacksonville, Florida 32256, United States
  • Ashild Peters
    North Miami, Florida 33161, United States
  • Ashild Peters
    Orlando, Florida 32801, United States
  • Ashild Peters
    Tampa, Florida 33614, United States
  • Ashild Peters
    Alpharetta, Georgia 30341, United States
  • Ashild Peters
    Lincolnwood, Illinois 60712, United States
  • Ashild Peters
    Boston, Massachusetts 02131, United States
  • Ashild Peters
    New Bedford, Massachusetts 02740, United States
  • Ashild Peters
    Flowood, Mississippi 39232, United States
  • Ashild Peters
    Saint Louis, Missouri 63141, United States
  • Ashild Peters
    Las Vegas, Nevada 89102, United States
  • Ashild Peters
    Oklahoma City, Oklahoma 73106, United States
  • Ashild Peters
    Portland, Oregon 97214, United States
  • Ashild Peters
    Salem, Oregon 97301, United States
  • Ashild Peters
    Memphis, Tennessee 38119, United States
  • Ashild Peters
    Austin, Texas 78737, United States
  • Ashild Peters
    Dallas, Texas 75231, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Apr 2020, 13 months.

Results were first posted in Feb 2025, 4 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2019
First posted
Feb 15, 2019
StartActual
Mar 7, 2019
Primary completionActual
Apr 24, 2020
CompletionActual
Apr 24, 2020
Results first posted
Feb 6, 2025
Last update
Feb 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03841773
Responsible party
Sponsor
First posted
Feb 15, 2019
Start date
Mar 7, 2019
Primary completion
Apr 24, 2020
Completion
Apr 24, 2020
Results posted
Feb 6, 2025
Last update
Feb 6, 2025

Study contacts

Gregory M Sullivan, MD
study director · Tonix Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclobenzaprine

Start the discussion